Copegus and Toprol-xl drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Copegus (ribavirin) and Toprol-xl (metoprolol succinate). Common drug interactions include menstrual disorder among females and myocardial infarction among males.
The phase IV clinical study analyzes what interactions people have when they take Copegus and Toprol-xl. It is created by eHealthMe based on reports of 32 people who take the same drugs from the FDA, and is updated regularly.
What is Copegus?
Copegus has active ingredients of ribavirin. It is often used in hepatitis c. eHealthMe is studying from 15,115 Copegus users. Check the latest studies of Copegus.
What is Toprol-xl?
Toprol-xl has active ingredients of metoprolol succinate. It is often used in high blood pressure. eHealthMe is studying from 40,636 Toprol-xl users. Check the latest studies of Toprol-xl.
32 people who take Copegus and Toprol-xl together, and have interactions are studied.

What are the common drug interactions of Copegus and Toprol-Xl, by gender? *:
female:
- Menstrual disorder (disease of menstrual cycle)
- Mood swings (an extreme or rapid change in mood)
- Nasal congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels)
- Red blood cell sedimentation rate increased
- Throat irritation
- Tinea infection (fungal skin infection)
- Tonsillitis (inflammation of tonsil)
- Abdominal pain
- Alanine aminotransferase increased
- Aspartate aminotransferase increased
male:
- Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
- Neuropathy peripheral (surface nerve damage)
- Fatigue (feeling of tiredness)
- Helicobacter infection (helicobacter pylori (h. pylori) infects stomach)
- Skin discolouration (change of skin colour)
- Vomiting
- White blood cell count decreased
- Acute respiratory failure
- Alkalosis
- Alopecia (absence of hair from areas of the body)
What are the common drug interactions of Copegus and Toprol-Xl, by age (0-1 to 60+)? *:
0-1:
n/a
2-9:
n/a
10-19:
n/a
20-29:
n/a
30-39:
- Abdominal pain
- Blood calcium decreased
- Dehydration (dryness resulting from the removal of water)
- Heart rate increased
- Infusion site reaction
- Renal disorder (kidney disease)
- Rheumatoid arthritis (a chronic progressive disease causing inflammation in the joints)
- Tooth abscess (pus formation in tooth)
- Vision blurred
- Weight fluctuation
40-49:
- Dehydration (dryness resulting from the removal of water)
- Depression
- Epistaxis (bleed from the nose)
- Fatigue (feeling of tiredness)
- Nausea (feeling of having an urge to vomit)
- White blood cell count decreased
- Angina pectoris (chest pain due to ischemia of the heart muscle)
- Basedow's disease (autoimmune disease where the thyroid is overactive, producing an excessive amount of thyroid hormones)
- Blood potassium decreased
- Blood thyroid stimulating hormone decreased
50-59:
- Dry skin
- Palpitations (feelings or sensations that your heart is pounding or racing)
- Heart rate increased
- Loss of consciousness
- Pain
- Neuropathy peripheral (surface nerve damage)
- Alopecia (absence of hair from areas of the body)
- Cardiac failure congestive
- Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
- Depression
60+:
- Anaemia (lack of blood)
- Blood glucose increased
- Skin discolouration (change of skin colour)
- Cough
- Hyperhidrosis (abnormally increased sweating)
- Oropharyngeal pain
- Rhinorrhoea (watery mucus discharge from the nose)
- Tremor (trembling or shaking movements in one or more parts of your body)
- White blood cell count decreased
- Chest pain
What are the existing conditions these people have? *
- Mood Swings (an extreme or rapid change in mood): 5 people, 15.62%
- Depression: 5 people, 15.62%
- Facial Pain: 3 people, 9.38%
- Chest Pain: 2 people, 6.25%
* Approximation only. Some reports may have incomplete information.
Do you take Copegus and Toprol-xl?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
Browse all drug interactions of Copegus and Toprol-xl:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Copegus:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Toprol-xl:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Copegus and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Toprol-xl and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zRelated publications that referenced our studies
- Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .
- Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .
How the study uses the data?
The study uses data from the FDA. It is based on ribavirin and metoprolol succinate (the active ingredients of Copegus and Toprol-xl, respectively), and Copegus and Toprol-xl (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Drug interactions of Midazolam Hydrochloride and Moxifloxacin - 12 seconds ago
- Could Flonase cause Eczema Asteatotic? - 25 seconds ago
- Drug interactions of Methylphenidate and Ergocalciferol - 28 seconds ago
- Could Garcinia Cambogi cause Abdominal Pain Aggravated? - 32 seconds ago
- Could Trimethoprim cause Colitis? - 32 seconds ago
- Drug interactions of Erelzi and Pseudoephedrine Hydrochloride And Triprolidine Hydrochloride - 38 seconds ago
- Drug interactions of Cilostazol and Hydrocortisone - 59 seconds ago
- Could Proair Hfa cause Drowsiness? - a minute ago
- Could Furosemide cause Enlarged Prostate? - a minute ago
- Could Triazolam cause Calculus Bladder? - a minute ago